This suggests that mitochondrial dysfunction within CD38+CD8+ T cells contributes to their impaired immune response, highlighting a potential target for therapeutic intervention in tumor environments (Figure 4F and Table 1).[41]. The gene discussed is CD8A; the disease is neoplasm.